Isolation of Mesenchymal Stromal Cells From Peripheral Blood of ST Elevation Myocardial Infarction Patients
Isolation of Mesenchymal Stromal Cells From Peripheral Blood of ST Elevation Myocardial Infarction Patients
复制标题
DOI：
10.1111/aor.12829
复制
发表时间：
2017-02
影响因子：
2.4
通讯作者：
I. L. Pieper;Rachel Smith;J. Bishop;O. Aldalati;Alexander J Chase;G. Morgan;C. Thornton
中科院分区：
文献类型：
--
作者：
I. L. Pieper;Rachel Smith;J. Bishop;O. Aldalati;Alexander J Chase;G. Morgan;C. Thornton
骨髓间充质干细胞（MSCs）在心肌梗死患者的治疗中显示出了潜在的治疗潜力。然而，骨髓需要侵入性采集技术。因此，目的是进行一项可行性研究，使用自体外周血（PB）作为骨髓间充质干细胞和血小板裂解物（PL）的来源，一种潜在的新型治疗干预急性ST段抬高心肌梗死（STEMI）患者。从STEMI患者和健康对照血液制备自体PL和MSC。通过三系分化和流式细胞术分析MSC。从83%的患者（n = 6）中分离出PB MSC，但未从对照中分离出PB MSC。在第一次传代中使用PL是可行的，但由于体积的原因，在随后的传代中使用PL是不可行的。总之，PB是一种有前途的骨髓替代品。它否定了对侵入性采集技术的需求，并降低了常规使用抗凝剂和抗血小板药物治疗的患者人群的出血风险。
Bone marrow mesenchymal stromal cells (MSCs) have shown therapeutic potential in the treatment of myocardial infarction patients. However, bone marrow requires invasive harvesting techniques. Therefore, the aim was to carry out a feasibility study of using autologous peripheral blood (PB) as a source for MSCs and platelet lysate (PL), a potential novel therapeutic intervention in acute ST elevation myocardial infarction (STEMI) patients. Autologous PL and MSCs were prepared from STEMI patient and healthy control blood. MSCs were analyzed by trilineage differentiation and flow cytometry. PB MSCs were isolated from 83% of patients (n = 6) but not from controls. The use of PL was feasible in the first passage but not in subsequent ones due to volume. To conclude, PB is a promising alternative to bone marrow. It negates the need for invasive harvesting techniques, and reduces hemorrhagic risk in this patient population routinely managed with anticoagulant and antiplatelet agents.